Suppr超能文献

COVID-19 大流行期间风湿性疾病患者擅自更改免疫抑制剂:一项患者调查的横断面分析。

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey.

机构信息

School of Medicine, University of Tuebingen, Tübingen, Germany.

Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-Inflammatory Diseases and Department of Internal Medicine II (Oncology, Hematology, Immunology, Rheumatology), University Hospital Tuebingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany.

出版信息

Rheumatol Int. 2023 Jul;43(7):1363-1367. doi: 10.1007/s00296-023-05311-8. Epub 2023 Mar 29.

Abstract

This study provides insight in behavior and perspective of rheumatic patients during the first COVID-19 wave. Especially, we analyzed the patients' fear of COVID-19 and unauthorized change of immunosuppressive medication in consequence of their fear. We hereby provide data from 877 patients with valuable insights into the patients' point of view. We retrospectively interviewed patients of our rheumatic university outpatient clinic. This way, we collected information about the patients' personal point of view. Data like the rheumatic diagnosis and immunosuppressive medication was extracted from the health records. Statistical analysis was conducted using IBM® SPSS® Statistics (version 26). A total of 877 patients were included into our study. We could show that fear of COVID-19 was clearly present in rheumatic patients. Higher fear levels seem to be associated with comorbidity burden. Unauthorized change of immunosuppressive medication was rare in our study (5%). In our study we provide novel insight into patients' point of view and behavior of rheumatic patients. Unauthorized change of immunosuppressive medication was rare (5%) as seen in other studies. The low rate of unauthorized change and high rate of compliance is reassuring since good disease control appears to be prognostically important in the progression of COVID-19 disease. Therefore, as the pandemic continues, treatment decisions should be made in close consultation between patient and practitioner to improve adherence and reduce morbidity and mortality.

摘要

这项研究提供了关于风湿患者在第一波 COVID-19 期间的行为和观点的深入了解。特别是,我们分析了患者对 COVID-19 的恐惧,以及由于这种恐惧而导致的免疫抑制药物的未经授权的改变。我们在此提供了来自 877 名患者的数据,为患者的观点提供了有价值的见解。我们回顾性地采访了我们风湿大学门诊的患者。通过这种方式,我们收集了患者个人观点的信息。数据如风湿诊断和免疫抑制药物是从健康记录中提取的。使用 IBM® SPSS® Statistics(版本 26)进行统计分析。共有 877 名患者纳入我们的研究。我们可以表明,风湿患者明显存在对 COVID-19 的恐惧。更高的恐惧水平似乎与合并症负担有关。在我们的研究中,未经授权改变免疫抑制药物的情况很少见(5%)。在我们的研究中,我们提供了风湿患者观点和行为的新见解。未经授权改变免疫抑制药物的情况在其他研究中也很少见(5%)。未经授权改变药物的低发生率和高遵从率令人安心,因为良好的疾病控制在 COVID-19 疾病的进展中似乎具有预后重要性。因此,随着大流行的继续,治疗决策应该在患者和医生之间进行密切协商,以提高遵从性并降低发病率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c577/10185569/9266348901c9/296_2023_5311_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验